Literature DB >> 8485617

Effects of dicentrine on haemodynamic, plasma lipid, lipoprotein level and vascular reactivity in hyperlipidaemic rats.

S M Yu1, Y F Kang, C C Chen, C M Teng.   

Abstract

1. The effects of dicentrine on haemodynamic, plasma lipid, lipoprotein level and vascular reactivity were investigated in Wistar-Kyoto (WKY) and spontaneously hypertensive (SH) rats, fed a high fat-high cholesterol diet. 2. In high fat-high cholesterol (HF-HC) diet fed WKY and SH rats, oral administration of dicentrine (5 and 10 mg kg-1, twice a day) for 4 weeks caused significant reductions in total plasma cholesterol (CE) by reducing the low density lipoprotein (LDL) fraction, and reductions in total plasma triglyceride (TG) by reducing the very low density lipoprotein (VLDL) fraction. 3. Dicentrine therapy was associated with increased high density lipoprotein (HDL)-cholesterol levels; thus the ratio of total plasma cholesterol to HDL-cholesterol was improved. 4. In HF-HC diet fed conscious WKY and SH rats, oral administration of dicentrine (5 and 10 mg kg-1, twice a day) also evoked dose-related decreases in mean arterial pressure (MAP) which were of greater magnitude in SH rats. Neither dose of dicentrine caused a significant change in heart rate (HR). 5. The aortic arches from SH rats fed the HF-HC diet for 8 weeks were significantly more affected by the atherosclerotic lesions than the abdominal aortae and renal arteries of WKY and SH rats. Oral administration of dicentrine (5 and 10 mg kg-1) for 4 weeks did not diminish the atherosclerotic lesion areas in WKY and SH rats. 6. In aortae of the hyperlipidaemic rats, significantly attenuated EC50 values and augmented maximal responses for phenylephrine-induced contraction were obtained. Endothelium-dependent relaxation to acetylcholine was abolished, while endothelium-independent relaxation to nitroprusside was well preserved. Dicentrine therapy caused significantly augmented EC50 values and attenuated maximal responses for phenylephrine-induced contraction in hyperlipidaemic rats. However, dicentrine neither prevented the impaired relaxation to acetylcholine, nor affected the relaxation to nitroprusside during atherosclerosis progression.7. It is concluded that dicentrine decreases MAP, plasma CE, LDL-CE, plasma TG, VLDL-TG,vascular hyperreactivity to phenylephrine and increases HDL-CE levels. Dicentrine may thus hold potential for the reduction of two of the major risk factors, hypertension and hyperlipidaemia, for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485617      PMCID: PMC1908156          DOI: 10.1111/j.1476-5381.1993.tb13505.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  A new enzymatic method for determination of serum choline-containing phospholipids.

Authors:  M Takayama; S Itoh; T Nagasaki; I Tanimizu
Journal:  Clin Chim Acta       Date:  1977-08-15       Impact factor: 3.786

2.  Enzymatic determination of total cholesterol in serum.

Authors:  P Roeschlau; E Bernt; W Gruber
Journal:  Z Klin Chem Klin Biochem       Date:  1974-05

Review 3.  The influence of hypertension and other hemodynamic factors in atherogenesis.

Authors:  A V Chobanian
Journal:  Prog Cardiovasc Dis       Date:  1983 Nov-Dec       Impact factor: 8.194

4.  Disturbance of cholesterol and bile acid metabolism in spontaneously hypertensive rats (SHR).

Authors:  K Uchida; Y Nomura; M Kadowaki; H Takase; N Takeuchi
Journal:  J Biochem       Date:  1978-11       Impact factor: 3.387

5.  Effect of cholesterol feeding on apo B and apo E concentrations and distributions in euthyroid and hypothyroid rats.

Authors:  J G DeLamatre; P S Roheim
Journal:  J Lipid Res       Date:  1981-02       Impact factor: 5.922

6.  Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.

Authors:  B R Krause; R S Newton
Journal:  J Lipid Res       Date:  1985-08       Impact factor: 5.922

7.  Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys.

Authors:  D D Heistad; M L Armstrong; M L Marcus; D J Piegors; A L Mark
Journal:  Circ Res       Date:  1984-06       Impact factor: 17.367

8.  A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study.

Authors:  W P Castelli; K Anderson
Journal:  Am J Med       Date:  1986-02-14       Impact factor: 4.965

9.  Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3.

Authors:  P N Demacker; D F van Sommeren-Zondag; A F Stalenhoef; P M Stuyt; A van't Laar
Journal:  Clin Chem       Date:  1983-04       Impact factor: 8.327

10.  Cholesterol potentiates the coronary artery response to norepinephrine in anesthetized and conscious dogs.

Authors:  C Rosendorff; J I Hoffman; E D Verrier; J Rouleau; L E Boerboom
Journal:  Circ Res       Date:  1981-03       Impact factor: 17.367

View more
  4 in total

1.  Mechanisms of vasorelaxation induced by N-allylsecoboldine in rat thoracic aorta.

Authors:  S M Yu; S S Lee; Y S Hou; C M Teng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

Review 2.  Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome.

Authors:  Fei-Xuan Wang; Nan Zhu; Fan Zhou; Dong-Xiang Lin
Journal:  Molecules       Date:  2021-10-10       Impact factor: 4.411

3.  Plant derived aporphinic alkaloid S-(+)-dicentrine induces antinociceptive effect in both acute and chronic inflammatory pain models: evidence for a role of TRPA1 channels.

Authors:  Deise Prehs Montrucchio; Marina Machado Córdova; Adair Roberto Soares Santos
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

Review 4.  A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).

Authors:  Yueping Jiang; Min Liu; Haitao Liu; Shao Liu
Journal:  Phytochem Rev       Date:  2020-04-24       Impact factor: 5.374

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.